Sentinel
Rebuild and rebalance a worn-down immune system.
In this protocol
Overview
How it runs
Thymosin Alpha-1 2-3x weekly; LL-37 in short supervised courses.
Thymosin Alpha-1 retrains immune balance while LL-37 adds direct antimicrobial firepower.
Questions
Who is the Sentinel stack designed for?⌄
It's designed for people with a worn-down or imbalanced immune system - whether from chronic illness, repeated infections, or a prolonged period of immune underperformance. It's not a general wellness stack; it's a targeted clinical immune protocol.
How is this stack run?⌄
Thymosin Alpha-1 is injected subcutaneously 2 to 3 times per week, typically for 4 to 12 weeks. LL-37 is used in short, supervised courses - the timing and duration of LL-37 are set by your clinician based on your situation.
What does Thymosin Alpha-1 actually do?⌄
It trains and balances the immune system by strengthening T-cell function and resilience. It's described as retraining immune balance rather than simply stimulating the immune system - making it appropriate for both underactive and dysregulated immune states.
Why is LL-37 described as needing supervision?⌄
LL-37 is a potent antimicrobial peptide used in short courses because of the risk of injection-site reactions and its specialized application. It's not a peptide that's dosed loosely - it requires clinician oversight to use safely and effectively.
Are there safety concerns with either peptide?⌄
Thymosin Alpha-1 is well tolerated with a strong clinical record. LL-37 can cause injection-site reactions and is used in specialized, supervised settings. Neither carries exclusion flags for pregnancy or cancer history in the data, but your full health history is reviewed at consult.
Is Thymosin Alpha-1 FDA-approved?⌄
Thymosin Alpha-1 is approved abroad as Zadaxin and is compounded in the US. LL-37 is a research compound. The regulatory status of each is reviewed with you at your consult.
Can this stack help prevent illness, or is it only for recovery?⌄
Thymosin Alpha-1 is used both for immune recovery and as a proactive immune-strengthening protocol. LL-37's use is more acute - it's most applicable when there is an active or recent infection context. Your clinician will help you determine the appropriate use case.
Run this protocol safely
A licensed provider in the PepDepo network sets your exact protocol and dosing.
Book a consultEducation only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.